Syncom Formulations Share Price for 2025, 2026 upto 2030
The Syncom Formulations share price has become a topic of growing interest among small and medium investors in India. With the pharmaceutical sector expanding rapidly, understanding how Syncom Formulations performs can help investors make smart decisions. Many people researching iepf unclaimed shares or looking for affordable pharma stocks often stumble upon Syncom due to its steady presence in the market.
What is Syncom Formulations (India) Limited?
Syncom Formulations (India) Limited is a well-established pharmaceutical manufacturing company headquartered in Indore, Madhya Pradesh. Founded in 1988, it became a public limited company in 1992 and has since grown its product range across 500+ formulations. The company manufactures tablets, capsules, syrups, injections, and ointments that cater to both domestic and international markets.
Its manufacturing facility in Pithampur is WHO-GMP certified and follows strict quality guidelines. The company also exports its products to more than 25 countries, creating a strong base in developing markets. This steady operational growth contributes to the stability of the Syncom Formulations share price over time.
Current Syncom Formulations Share Price and Market Overview
As of the latest update, the Syncom Formulations share price trades around ₹16.67 per share on the NSE (SYNCOMF). The company’s market capitalization is approximately ₹1,560 crore, positioning it among the smaller yet significant pharmaceutical players in India.
| Metric | Data (Approximate) |
|---|---|
| Current Share Price | ₹16.67 |
| 52-Week High / Low | ₹23.87 / ₹14.10 |
| Market Capitalization | ₹1,560 crore |
| P/E Ratio | 27x |
| Book Value per Share | ₹3.64 |
| Dividend Yield | 0% |
| Debt to Equity Ratio | Very Low |
This table highlights that while Syncom trades at a modest price, it maintains a solid valuation with low debt and moderate earnings growth. Investors monitoring the Syncom Formulations share price should note that it remains below its 52-week high, suggesting potential room for future appreciation if growth continues.
Business Operations and Financial Strength
Syncom Formulations has established itself as a reliable manufacturer of affordable generic medicines. The company’s focus on formulations instead of raw materials provides it with better control over pricing and margins. It also benefits from India’s booming pharmaceutical exports, especially to African and Southeast Asian nations.
In recent financial reports, the company posted annual revenue of around ₹480 crore and a net profit of approximately ₹48 crore. These figures reflect a profit margin of nearly 10%, which is healthy for a mid-sized pharma company. The operating efficiency and low leverage add to the confidence surrounding the Syncom Formulations share price stability.
Syncom’s Product Range and Global Reach
The company offers a wide variety of products across therapeutic segments like antibiotics, antipyretics, pain management, and nutritional supplements. Its international presence includes countries in Asia, Africa, and Latin America, supported by over 400 product registrations worldwide.
The company’s expansion into the injectables segment, increasing capacity from 200 lakh to 300 lakh units annually, demonstrates its intent to grow in the high-demand injectable market. This move could positively influence the Syncom Formulations share price in the coming quarters.
| Product Category | Examples | Target Markets |
|---|---|---|
| Tablets & Capsules | Antibiotics, Painkillers | Domestic & African Markets |
| Liquid Syrups | Cough & Fever Remedies | Asia, Latin America |
| Injections | Parenteral Drugs | Export Markets |
| Ointments & Creams | Skin & Pain Relief | Local Distribution |
Ownership and Shareholding Pattern
Syncom Formulations maintains a promoter holding of around 50.57%, which indicates strong insider confidence. Foreign institutional investors hold less than 0.1%, while the rest belongs to retail and domestic investors. A higher promoter stake typically suggests long-term commitment to the company’s growth, and this trust often influences the Syncom Formulations share price positively.
| Shareholder Type | Percentage Holding |
|---|---|
| Promoters | 50.57% |
| Retail Investors | 49.33% |
| Foreign Institutional Investors | 0.10% |
Factors Influencing Syncom Formulations Share Price
Several elements play a role in shaping the Syncom Formulations share price. The company’s future value depends on both internal performance and external industry factors.
First, the pharmaceutical export market directly impacts sales and profits. A rise in demand for affordable drugs in developing countries can drive revenue upward. Second, domestic policies around healthcare and pricing affect margins. Lastly, market sentiment plays a big part, as investor confidence in small-cap pharma stocks often swings based on quarterly results and industry news.
In the middle of its expansion, Syncom also explores equity-related instruments similar to ccps shares, which may help raise funds for further product development or factory upgrades. Investors tracking such actions should stay updated with company announcements for potential opportunities.
Financial Performance and Growth Trends
Syncom Formulations continues to post consistent quarterly growth. In the first quarter of FY26, the company reported ₹116 crore in sales with a net profit of ₹15.75 crore. The margins remain stable due to efficient production costs and growing export contributions.
Over the past five years, Syncom’s revenue has grown at a compound annual growth rate (CAGR) of about 12%, indicating sustained progress. The management’s conservative debt policy and strategic expansion into international markets give it a strong foundation. Investors tracking Syncom Formulations share price see this growth trend as a reason for optimism.
| Financial Year | Revenue (₹ Crore) | Net Profit (₹ Crore) |
|---|---|---|
| 2021 | 330 | 32 |
| 2022 | 375 | 40 |
| 2023 | 410 | 46 |
| 2024 | 480 | 49 |
This upward trend proves that Syncom’s focus on efficient operations and export diversification pays off. The improvement in profits without excessive borrowing reinforces the company’s long-term sustainability.
Competitive Position in the Pharmaceutical Market
The Indian pharmaceutical industry is highly competitive, dominated by major players like Sun Pharma, Dr. Reddy’s, and Cipla. Despite its smaller scale, Syncom Formulations has carved out a space by focusing on affordable generics and export quality assurance.
Its WHO-GMP certification gives it credibility in the global market. This reputation can boost future collaborations and distribution deals, eventually supporting an upward trend in the Syncom Formulations share price.
Risks Associated with Syncom Formulations Stock
No investment is without risks, and Syncom is no exception. The major risk factors include price volatility, regulatory compliance, and competition from larger pharmaceutical companies. Since Syncom’s international sales are exposed to currency fluctuations, any major exchange rate change could affect profitability.
Moreover, being a small-cap company, it may experience sharp movements in the Syncom Formulations share price based on limited liquidity and investor sentiment. Still, the company’s financial stability and operational efficiency help reduce these risks to an extent.
Investor Outlook and Future Potential
Looking ahead, Syncom Formulations aims to strengthen its global footprint and introduce new therapeutic products. The Indian government’s support for Make in India and affordable healthcare initiatives aligns with Syncom’s business model.
With continued revenue growth and capacity expansion, analysts expect the Syncom Formulations share price to remain stable in the short term and potentially rise with sustained earnings. For long-term investors seeking steady growth, the company offers an interesting opportunity at a reasonable valuation.
Syncom Formulations Share Price – 2025
| Quarter | Assumed Avg Price (₹) | Notes |
|---|---|---|
| Q1 2025 | 16.5 | Around current trading zone |
| Q2 2025 | 17.2 | Mild recovery from lows |
| Q3 2025 | 17.8 | Export orders kick in |
| Q4 2025 | 18.5 | Year-end pharma sentiment |
Syncom Formulations Share Price – 2026
| Quarter | Assumed Avg Price (₹) | Notes |
|---|---|---|
| Q1 2026 | 18.8 | Stable around 18–19 |
| Q2 2026 | 19.4 | Better margins |
| Q3 2026 | 20.1 | Capacity utilization up |
| Q4 2026 | 21.0 | Small-cap pharma re-rating |
Syncom Formulations Share Price – 2027
| Quarter | Assumed Avg Price (₹) | Notes |
|---|---|---|
| Q1 2027 | 21.4 | Continuation of 2026 trend |
| Q2 2027 | 22.0 | Steady growth |
| Q3 2027 | 22.8 | Strong export cycle |
| Q4 2027 | 23.6 | New product traction |
Syncom Formulations Share Price – 2028
| Quarter | Assumed Avg Price (₹) | Notes |
|---|---|---|
| Q1 2028 | 24.0 | Above old 52-week high |
| Q2 2028 | 24.7 | Market cap expansion |
| Q3 2028 | 25.5 | Pharma sector supportive |
| Q4 2028 | 26.4 | Year-end buying |
Syncom Formulations Share Price – 2029
| Quarter | Assumed Avg Price (₹) | Notes |
|---|---|---|
| Q1 2029 | 26.9 | Consolidation zone |
| Q2 2029 | 27.6 | Better earnings |
| Q3 2029 | 28.4 | Possible bonus/split buzz |
| Q4 2029 | 29.3 | Valuation stretch starts |
Syncom Formulations Share Price – 2030
| Quarter | Assumed Avg Price (₹) | Notes |
|---|---|---|
| Q1 2030 | 29.8 | Mature uptrend |
| Q2 2030 | 30.6 | Slow, healthy rise |
| Q3 2030 | 31.5 | Export + domestic demand |
| Q4 2030 | 32.5 | Decade high range |
Conclusion
The Syncom Formulations share price reflects the company’s evolution from a small domestic manufacturer to an emerging international pharma brand. Its strong promoter holding, consistent financial results, and minimal debt make it an attractive choice for cautious investors.
As the global demand for affordable medicines continues to rise, Syncom’s product diversity and export strategy could enhance profitability further. However, investors must stay informed about regulatory changes, competition, and quarterly earnings before making decisions.
In conclusion, Syncom Formulations (India) Limited stands as a promising yet cautious investment option in the Indian pharmaceutical landscape. The company’s transparent operations, export growth, and innovation-driven manufacturing approach continue to draw investor attention, ensuring that the Syncom Formulations share price remains a significant topic in discussions around emerging pharma stocks in India.